Triple-Drug attack shows promise against blood cancer

NCT ID NCT03580928

First seen Feb 14, 2026 · Last updated Jun 12, 2026 · Updated 15 times

Summary

This study tested a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) as a first treatment for people with chronic lymphocytic leukemia (CLL) who had not received prior therapy. The goal was to see if the combination could clear cancer cells from the bone marrow. A total of 72 participants took part. The approach aims to control the disease, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Lifespan Cancer Institute

    Providence, Rhode Island, 02903, United States

  • Stamford Hospital/Bennett Cancer Center

    Stamford, Connecticut, 06904, United States

Conditions

Explore the condition pages connected to this study.